A Multicenter Phase 2 Single-arm Proof-of-concept Trial to Assess the Efficacy and Safety of Ustekinumab in Association With Prednisone for the Treatment of Non-infectious Severe Uveitis (NISU) (USTEKINISU)
Sponsor: Centre Hospitalier Universitaire Dijon
Terminated
The long inclusion period meant that the question could not be answered within an appropriate timeframe.
Other terminated trials from Centre Hospitalier Universitaire Dijon
- Nephrostomy · Mar 2026
- Surgery for Cataract · Jan 2026
- Ibrutinib Treatment · Aug 2025
- Macular Telangiectasia · Phase PHASE3 · Mar 2025
- Septic Shock · Phase NA · Jun 2024
See all terminations from Centre Hospitalier Universitaire Dijon
This PHASE2 trial investigates Patients With Newly Diagnosed Active NISU and is currently terminated or withdrawn. Centre Hospitalier Universitaire Dijon leads this study, which shows 11 recorded versions since 2019 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Feb 2024 — Jul 2024 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
May 2021 — Feb 2024 [monthly]
Recruiting PHASE2
-
Mar 2021 — May 2021 [monthly]
Recruiting PHASE2
▶ Show 6 earlier versions
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE2
-
Apr 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Mar 2020 — Apr 2020 [monthly]
Recruiting PHASE2
-
Oct 2019 — Mar 2020 [monthly]
Recruiting PHASE2
-
Sep 2019 — Oct 2019 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Mar 2019 — Sep 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Centre Hospitalier Universitaire Dijon
For direct contact, visit the study record on ClinicalTrials.gov .